Ciclofilin Pharmaceuticals Invited to Present Hepatitis B Drug Data at Cambridge Healthtech Institute’s Eleventh Annual Drug Discovery Chemistry Conference
April 19, 2016 09:00 ET
|
Ciclofilin Pharmaceuticals Inc.
SAN DIEGO, April 19, 2016 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company"), a privately held biotech, announced today that it will discuss important new data for...
Ciclofilin Pharmaceuticals Welcomes Dr. Nikolai Naoumov to Its Scientific Advisory Board
February 04, 2016 09:00 ET
|
Ciclofilin Pharmaceuticals Inc.
SAN DIEGO, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company"), a privately held biotech, announced today that Dr. Nikolai Naoumov, a world-renowned...
Ciclofilin Pharmaceuticals Announces Formation of World-Class HBV and Liver Disease Scientific Advisory Board
December 02, 2015 09:30 ET
|
Ciclofilin Pharmaceuticals Inc.
SAN DIEGO, Dec. 2, 2015 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company"), a privately held biotech, announced today that it has assembled a world-class team of...
Ciclofilin Pharmaceuticals to Present at HEP DART 2015
November 30, 2015 09:30 ET
|
Ciclofilin Pharmaceuticals Inc.
SAN DIEGO, Nov. 30, 2015 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company"), a privately held biotech, announced today that it will discuss the antiviral and...
Ciclofilin Pharmaceuticals Receives Notice of Patent Allowance for Novel Cyclophilin Inhibitor
August 04, 2015 09:30 ET
|
Ciclofilin Pharmaceuticals Inc.
SAN DIEGO, Aug. 4, 2015 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company"), a privately held biotech, announced today that it has received a Notice of Allowance from...
Ciclofilin Pharmaceuticals' Lead Antiviral Drug Reduces Liver HBV DNA
July 28, 2015 07:30 ET
|
Ciclofilin Pharmaceuticals Inc.
SAN DIEGO, July 28, 2015 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company"), a hepatitis B virus ("HBV") drug developer, announced today its lead antiviral drug...
Ciclofilin Pharmaceuticals Invited to Present at Jefferies Conference
July 27, 2015 10:06 ET
|
Ciclofilin Pharmaceuticals Inc.
SAN DIEGO, July 27, 2015 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals Inc. today announced that its Chief Executive Officer, Dr. Robert T. Foster, will discuss the company's hepatitis B development...
Ciclofilin Pharmaceuticals' HBV Drug Demonstrates Anti-Fibrotic Activity
June 24, 2015 08:00 ET
|
Ciclofilin Pharmaceuticals Inc.
SAN DIEGO, June 24, 2015 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company"), a hepatitis B virus ("HBV") drug developer, announced today its lead antiviral drug...
Ciclofilin Pharmaceuticals Appoints Michael Kamdar as President
May 04, 2015 08:00 ET
|
Ciclofilin Pharmaceuticals Inc.
SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals Inc., a hepatitis B virus ("HBV") drug developer, announced today the appointment of Michael Kamdar as President.
Mr. Kamdar has...
Ciclofilin Pharmaceuticals Granted Patent in Japan for Cyclophilin Inhibitor Drugs
February 24, 2015 09:00 ET
|
Ciclofilin Pharmaceuticals Inc.
SAN DIEGO, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals, Inc. ("Ciclofilin" or the "Company"), a biotechnology company focused on the development of broad spectrum antivirals, today...